3500 ORAL Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma

Authors:
  • GAG.K. Abou Alfa
    G.K. Abou Alfa
  • PJP. Johnson
    P. Johnson
  • JKJ. Knox
    J. Knox
  • JLJ. Lacava
    J. Lacava
  • TLT. Leung
    T. Leung
  • AMA. Mori
    A. Mori
  • MLM.A. Leberre
    M.A. Leberre
  • DVD. Voliotis
    D. Voliotis
  • LSL. Saltz
    L. Saltz

Abstract
No abstract available